International Clinical Trial: A Randomized, Controlled, Double-Blind, Multicenter Clinical Study to Evaluate the Efficacy of Alkaline Negative-Potential Monomolecular High-Activity Water (AEMW) in Ameliorating Patient-Reported Adverse Reactions in Advanced Breast Cancer Patients Treated with Trastuzumab Deruxtecan

Geneva, April 28 -- International Clinical Trials Registry received information related to the study (ChiCTR2600122534) titled 'A Randomized, Controlled, Double-Blind, Multicenter Clinical Study to Evaluate the Efficacy of Alkaline Negative-Potential Monomolecular High-Activity Water (AEMW) in Ameliorating Patient-Reported Adverse Reactions in Advanced Breast Cancer Patients Treated with Trastuzumab Deruxtecan' on April 14.

Study Type: Interventional study

Study Design: Parallel

Primary Sponsor: The First Affiliated Hospital of Dalian Medical University

Condition: Breast cancer Perceived adverse reactions associated with detrastuzumab treatment

Intervention: Control group:Drink placebo water

Recruitment Status: Not Recruiting

P...